As previously disclosed, on October 1, 2020, AMAG Pharmaceuticals, Inc. (‘AMAG’), entered into an Agreement and Plan of Merger (the ‘Merger Agreement’) with Covis Group S.à r.l. (‘Covis’), Covis Mergerco Inc. and an indirect wholly owned subsidiary of Covis (‘Merger Sub’), and solely with respect to certain sections therein, Covis Finco S.à r.l. (‘Covis Finco’). In accordance with the Merger Agreement, at the effective time of the Merger, each of John A. Fallon M.D., Paul Fonteyne, David Johnson, Scott Myers, Katherine O’Brien, Anne M. Phillips, M.D., FRCPC, Gino Santini, Davey S. Scoon, CPA and James Sulat resigned from the board of directors of AMAG. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, Michael Porter, as the director of Merger Sub as of immediately prior to the effective time of the Merger, became the director of AMAG. Immediately upon the Merger, Michael Porter assumed the role of President of AMAG. Francesco Tallarico assumed the role of Corporate Secretary of AMAG, in each case, replacing the current holder of that office.